revumenib
syndax pharma
['revumenib', 'leusm']
striking results for a single agent treatment in heavily pretreated patients (median of 4 pevious treatment lines!)
median os of 7 months!
for reference on outcomes prior to menin inhibitors #ash22, #leusm
kmt2ar mnpm1 
Research scholar @MDAndersonnews Leukemia Department| MD '21 @AUB_Lebanon | My tweets are my own | RTs are not endorsements